Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 12/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31463303 | 0.97 | TDP1 (0.48) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31245821 | 0.93 | CA12 (0.49) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31245877 | 0.93 | CA12 (0.52) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL21842860 | 0.93 | CA12 (0.49) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25355103 | 0.89 | TDP1 (0.47) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL26935317 | 0.86 | CA12 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25963920 | 0.86 | CA12 (0.46) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL25181487 | 0.86 | CA12 (0.59) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL31284031 | 0.86 | CA12 (0.59) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL26722852 | 0.86 | EPHX2 (0.43) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545637-B2 | Extrahepatic targeted cationic lipid compound with high efficiency and low toxicity and its composition | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-02-10 | — | — | US | disclosed |
| EP-4663624-A1 | EXTRAHEPATIC TARGETED HIGH-EFFICIENCY AND LOW-TOXICITY CATIONIC LIPID COMPOUND AND COMPOSITION THEREOF | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250109092-A1 | EXTRAHEPATIC TARGETED CATIONIC LIPID COMPOUND WITH HIGH EFFICIENCY AND LOW TOXICITY AND ITS COMPOSITION | Beijing Youcarekechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2024164426-A1 | EXTRAHEPATIC TARGETED HIGH-EFFICIENCY AND LOW-TOXICITY CATIONIC LIPID COMPOUND AND COMPOSITION THEREOF | 北京悦康科创医药科技股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545637-B2 | Extrahepatic targeted cationic lipid compound with high efficiency and low toxicity and its composition | SLC10A1, SLC10A2, LIPC | TDP1 4699/4885CA12 966/4885CA1 3410/4885 |
| US-20250109092-A1 | EXTRAHEPATIC TARGETED CATIONIC LIPID COMPOUND WITH HIGH EFFICIENCY AND LOW TOXICITY AND ITS COMPOSITION | SLC10A1, LIPC, NPC1L1 | TDP1 4447/4885CA12 1502/4885CA1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.